undamentalytics Newsletter
Sign in

Exelixis, Inc. income statement

In fiscal 2025, Exelixis, Inc. reported revenue of $2.32bn, up 7.0% on the year before, operating income of $872m (a 37.6% margin) and net income of $783m, or $2.78 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2009Dec 20092010Dec 20102011Dec 20112012Dec 20122013Dec 20132014Dec 20142015Jan 20162016Dec 20162017Dec 20172018Dec 20182019Jan 20202020Jan 20212021Dec 20212022Dec 20222023Dec 20232024Jan 20252025Jan 2026LTMOct 2026
Revenue152185290473125371914528549689881,4351,6111,8302,1692,3202,497
Cost of revenue———————715263336535873768493
Gross profit———————1854378279359511,3821,5531,7582,0922,2362,404
Research and development23521115712917918996961121823375486948921,044910825835
Selling, general and administrative——3332515157116159206228293402460543492519565
General and administrative3433————————————————
Operating income−122−9190−122−201−224−121−281664393691102872011716058721,003
Interest expense139162539414133900———————
Income before tax−141−9277−148−245−261−162−70159452398131——————
Income tax−1−010−0−0004−2387719635250160159181
Net income−135−9276−145−238−261−162−70154690321112231182208521783885
Diluted EPS−$1.26−$0.85$0.58−$0.92−$1.33−$1.34−$0.77−$0.28$0.49$2.21$1.02$0.35$0.72$0.56$0.65$1.76$2.78$3.34
Diluted shares (average)107m109m130m160m184m194m209m251m312m313m315m318m322m325m321m296m282m265m
EBITDA−109−8196−117−198−222−120−271674443781193002221976339011,031

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: EXEL vs NTRAEXEL vs MRNAEXEL vs UTHR

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Exelixis, Inc.'s SEC filings (10-K and 10-Q), retrieved October 30, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Exelixis, Inc.